Literature DB >> 33711057

Modifications of the mechanical properties of in vivo tissue-engineered vascular grafts by chemical treatments for a short duration.

Tomoya Inoue1, Keiichi Kanda1, Masashi Yamanami1, Daisuke Kami2, Satoshi Gojo2, Hitoshi Yaku1.   

Abstract

In vivo tissue-engineered vascular grafts constructed in the subcutaneous spaces of graft recipients have functioned well clinically. Because the formation of vascular graft tissues depends on several recipient conditions, chemical pretreatments, such as dehydration by ethanol (ET) or crosslinking by glutaraldehyde (GA), have been attempted to improve the initial mechanical durability of the tissues. Here, we compared the effects of short-duration (10 min) chemical treatments on the mechanical properties of tissues. Tubular tissues (internal diameter, 5 mm) constructed in the subcutaneous tissues of beagle dogs (4 weeks, n = 3), were classified into three groups: raw tissue without any treatment (RAW), tissue dehydrated with 70% ET (ET), and tissue crosslinked with 0.6% GA (GA). Five mechanical parameters were measured: burst pressure, suture retention strength, ultimate tensile strength (UTS), ultimate strain (%), and Young's modulus. The tissues were also autologously re-embedded into the subcutaneous spaces of the same dogs for 4 weeks (n = 2) for the evaluation of histological responses. The burst pressure of the RAW group (1275.9 ± 254.0 mm Hg) was significantly lower than those of ET (2115.1 ± 262.2 mm Hg, p = 0.0298) and GA (2570.5 ± 282.6 mm Hg, p = 0.0017) groups. Suture retention strength, UTS or the ultimate strain did not differ significantly among the groups. Young's modulus of the ET group was the highest (RAW: 5.41 ± 1.16 MPa, ET: 12.28 ± 2.55 MPa, GA: 7.65 ± 1.18 MPa, p = 0.0185). No significant inflammatory tissue response or evidence of residual chemical toxicity was observed in samples implanted subcutaneously for four weeks. Therefore, short-duration ET and GA treatment might improve surgical handling and the mechanical properties of in vivo tissue-engineered vascular tissues to produce ideal grafts in terms of mechanical properties without interfering with histological responses.

Entities:  

Year:  2021        PMID: 33711057      PMCID: PMC7954299          DOI: 10.1371/journal.pone.0248346

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  28 in total

Review 1.  Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts: a review.

Authors:  Hiroaki Haruguchi; Satoshi Teraoka
Journal:  J Artif Organs       Date:  2003       Impact factor: 1.731

2.  Readily available tissue-engineered vascular grafts.

Authors:  Shannon L M Dahl; Alan P Kypson; Jeffrey H Lawson; Juliana L Blum; Justin T Strader; Yuling Li; Roberto J Manson; William E Tente; Louis DiBernardo; M Taylor Hensley; Riley Carter; Tiare P Williams; Heather L Prichard; Margaret S Dey; Keith G Begelman; Laura E Niklason
Journal:  Sci Transl Med       Date:  2011-02-02       Impact factor: 17.956

3.  Mechanical behavior of vessel wall: a comparative study of aorta, vena cava, and carotid artery.

Authors:  Frederick H Silver; Patrick B Snowhill; David J Foran
Journal:  Ann Biomed Eng       Date:  2003 Jul-Aug       Impact factor: 3.934

4.  Autogenous grafts made to order.

Authors:  C H Sparks
Journal:  Ann Thorac Surg       Date:  1969-08       Impact factor: 4.330

5.  A completely biological tissue-engineered human blood vessel.

Authors:  N L'Heureux; S Pâquet; R Labbé; L Germain; F A Auger
Journal:  FASEB J       Date:  1998-01       Impact factor: 5.191

6.  In vivo tissue-engineered small-caliber arterial graft prosthesis consisting of autologous tissue (biotube).

Authors:  Yasuhide Nakayama; Hatsue Ishibashi-Ueda; Keiichi Takamizawa
Journal:  Cell Transplant       Date:  2004       Impact factor: 4.064

7.  National Utilization and Outcomes of Redo Lower Extremity Bypass versus Endovascular Intervention after a Previous Failed Bypass.

Authors:  J Hunter Mehaffey; Alexander Shannon; Robert B Hawkins; Anna Fashandi; Margret C Tracci; Irving L Kron; Gilbert R Upchurch; William P Robinson
Journal:  Ann Vasc Surg       Date:  2017-09-07       Impact factor: 1.466

8.  Mechanical properties of human pericardium. Differences in viscoelastic response when compared with canine pericardium.

Authors:  J M Lee; D R Boughner
Journal:  Circ Res       Date:  1985-09       Impact factor: 17.367

9.  Tensile strength of human pericardium treated with glutaraldehyde.

Authors:  Hiromasa Yamashita; Shigeyuki Ozaki; Kiyotaka Iwasaki; Isamu Kawase; Yukinari Nozawa; Mitsuo Umezu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2012-04-27       Impact factor: 1.520

Review 10.  Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts.

Authors:  Michele Carrabba; Paolo Madeddu
Journal:  Front Bioeng Biotechnol       Date:  2018-04-17
View more
  3 in total

1.  From In Vitro to Perioperative Vascular Tissue Engineering: Shortening Production Time by Traceable Textile-Reinforcement.

Authors:  Saurav Ranjan Mohapatra; Elena Rama; Christoph Melcher; Tobias Call; Miriam Aischa Al Enezy-Ulbrich; Andrij Pich; Christian Apel; Fabian Kiessling; Stefan Jockenhoevel
Journal:  Tissue Eng Regen Med       Date:  2022-10-06       Impact factor: 4.451

2.  Pulmonary artery augmentation and aortic valve repair using novel tissue-engineered grafts.

Authors:  Hisayuki Hongu; Masaaki Yamagishi; Keiichi Kanda; Yoshinobu Maeda; Tomoya Inoue; Hiroki Nakatsuji; Hitoshi Yaku
Journal:  JTCVS Tech       Date:  2022-01-21

Review 3.  Small Diameter Cell-Free Tissue-Engineered Vascular Grafts: Biomaterials and Manufacture Techniques to Reach Suitable Mechanical Properties.

Authors:  María A Rodríguez-Soto; Camilo A Polanía-Sandoval; Andrés M Aragón-Rivera; Daniel Buitrago; María Ayala-Velásquez; Alejandro Velandia-Sánchez; Gabriela Peralta Peluffo; Juan C Cruz; Carolina Muñoz Camargo; Jaime Camacho-Mackenzie; Juan Guillermo Barrera-Carvajal; Juan Carlos Briceño
Journal:  Polymers (Basel)       Date:  2022-08-23       Impact factor: 4.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.